Fragment-based Drug Discovery Comprehensive Study by Type (Fragment Screening, Fragment Optimization), End-users (Academic and Research Institutions, Biopharmaceutical Companies, Contract Research Organizations), Technology (NMR Spectroscopy, Differential Scanning Fluorimetry (DSF) Assay, Fluorescence Polarization, Isothermal Titration Calorimetry, X-Ray Crystallography, Surface Plasmon Resonance (SPR), Others) Players and Region - Global Market Outlook to 2027

Report Objectives / Segmentation Covered

• Fragment Screening
• Fragment Optimization

• Academic and Research Institutions
• Biopharmaceutical Companies
• Contract Research Organizations

• NMR Spectroscopy
• Differential Scanning Fluorimetry (DSF) Assay
• Fluorescence Polarization
• Isothermal Titration Calorimetry
• X-Ray Crystallography
• Surface Plasmon Resonance (SPR)
• Others

• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • Italy
  • United Kingdom
  • Netherlands
  • Rest of Europe
• MEA
  • Middle East
  • Africa
• North America
  • United States
  • Canada
  • Mexico

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Dynamics
  • 3.1. Introduction
  • 3.2. Market Drivers
    • 3.2.1. Increasingly used in the Pharmaceutical Industry, For Reducing Attrition and Providing Leads for Previously Intractable Biological Targets
    • 3.2.2. Availability of Wide Range of Assay Options for High Hit Rates of Fragment-Based Screens
  • 3.3. Market Challenges
    • 3.3.1. Reduced Demand for Prescription Medicine
    • 3.3.2. Growing Competition from Generic Pharmaceuticals
    • 3.3.3. Pharmaceutical Fraud
    • 3.3.4. Rising Consumer Expectations and Difficulties Managing Brand Health
    • 3.3.5. Data Breaches and Other Cybersecurity Threats
    • 3.3.6. Supply Chain Disruptions
  • 3.4. Market Trends
    • 3.4.1. High-Tech Will Fuel Advancement in R&D
    • 3.4.2. Data Analytics Will Accelerate Biotechnology Innovation
    • 3.4.3. Emerging Markets Will Drive Innovation
    • 3.4.4. Increased Conflict between Affordability and Access
• 4. Market Factor Analysis
  • 4.1. Porters Five Forces
  • 4.2. Supply/Value Chain
  • 4.3. PESTEL analysis
  • 4.4. Market Entropy
  • 4.5. Patent/Trademark Analysis
• 5. Global Fragment-based Drug Discovery, by Type, End-users, Technology and Region (value) (2016-2021)
  • 5.1. Introduction
  • 5.2. Global Fragment-based Drug Discovery (Value)
    • 5.2.1. Global Fragment-based Drug Discovery by: Type (Value)
      • 5.2.1.1. Fragment Screening
      • 5.2.1.2. Fragment Optimization
    • 5.2.2. Global Fragment-based Drug Discovery by: End-users (Value)
      • 5.2.2.1. Academic and Research Institutions
      • 5.2.2.2. Biopharmaceutical Companies
      • 5.2.2.3. Contract Research Organizations
    • 5.2.3. Global Fragment-based Drug Discovery by: Technology (Value)
      • 5.2.3.1. NMR Spectroscopy
      • 5.2.3.2. Differential Scanning Fluorimetry (DSF) Assay
      • 5.2.3.3. Fluorescence Polarization
      • 5.2.3.4. Isothermal Titration Calorimetry
      • 5.2.3.5. X-Ray Crystallography
      • 5.2.3.6. Surface Plasmon Resonance (SPR)
      • 5.2.3.7. Others
    • 5.2.4. Global Fragment-based Drug Discovery Region
      • 5.2.4.1. South America
        • 5.2.4.1.1. Brazil
        • 5.2.4.1.2. Argentina
        • 5.2.4.1.3. Rest of South America
      • 5.2.4.2. Asia Pacific
        • 5.2.4.2.1. China
        • 5.2.4.2.2. Japan
        • 5.2.4.2.3. India
        • 5.2.4.2.4. South Korea
        • 5.2.4.2.5. Taiwan
        • 5.2.4.2.6. Australia
        • 5.2.4.2.7. Rest of Asia-Pacific
      • 5.2.4.3. Europe
        • 5.2.4.3.1. Germany
        • 5.2.4.3.2. France
        • 5.2.4.3.3. Italy
        • 5.2.4.3.4. United Kingdom
        • 5.2.4.3.5. Netherlands
        • 5.2.4.3.6. Rest of Europe
      • 5.2.4.4. MEA
        • 5.2.4.4.1. Middle East
        • 5.2.4.4.2. Africa
      • 5.2.4.5. North America
        • 5.2.4.5.1. United States
        • 5.2.4.5.2. Canada
        • 5.2.4.5.3. Mexico
• 6. Fragment-based Drug Discovery: Manufacturers/Players Analysis
  • 6.1. Competitive Landscape
    • 6.1.1. Market Share Analysis
      • 6.1.1.1. Top 3
      • 6.1.1.2. Top 5
  • 6.2. Peer Group Analysis (2021)
  • 6.3. BCG Matrix
  • 6.4. Company Profile
    • 6.4.1. Astex Pharmaceuticals (United Kingdom)
      • 6.4.1.1. Business Overview
      • 6.4.1.2. Products/Services Offerings
      • 6.4.1.3. Financial Analysis
      • 6.4.1.4. SWOT Analysis
    • 6.4.2. Alveus Pharmaceuticals (India)
      • 6.4.2.1. Business Overview
      • 6.4.2.2. Products/Services Offerings
      • 6.4.2.3. Financial Analysis
      • 6.4.2.4. SWOT Analysis
    • 6.4.3. Beactica (Sweden)
      • 6.4.3.1. Business Overview
      • 6.4.3.2. Products/Services Offerings
      • 6.4.3.3. Financial Analysis
      • 6.4.3.4. SWOT Analysis
    • 6.4.4. Charles River Laboratories (United States)
      • 6.4.4.1. Business Overview
      • 6.4.4.2. Products/Services Offerings
      • 6.4.4.3. Financial Analysis
      • 6.4.4.4. SWOT Analysis
    • 6.4.5. Crown Bioscience (United States)
      • 6.4.5.1. Business Overview
      • 6.4.5.2. Products/Services Offerings
      • 6.4.5.3. Financial Analysis
      • 6.4.5.4. SWOT Analysis
    • 6.4.6. Emerald BioStructures (United States)
      • 6.4.6.1. Business Overview
      • 6.4.6.2. Products/Services Offerings
      • 6.4.6.3. Financial Analysis
      • 6.4.6.4. SWOT Analysis
    • 6.4.7. Evotec (Germany)
      • 6.4.7.1. Business Overview
      • 6.4.7.2. Products/Services Offerings
      • 6.4.7.3. Financial Analysis
      • 6.4.7.4. SWOT Analysis
    • 6.4.8. Kinetic Discovery (United Kingdom)
      • 6.4.8.1. Business Overview
      • 6.4.8.2. Products/Services Offerings
      • 6.4.8.3. Financial Analysis
      • 6.4.8.4. SWOT Analysis
    • 6.4.9. Proteros Fragments (Germany)
      • 6.4.9.1. Business Overview
      • 6.4.9.2. Products/Services Offerings
      • 6.4.9.3. Financial Analysis
      • 6.4.9.4. SWOT Analysis
    • 6.4.10. Structure Based Design (United States)
      • 6.4.10.1. Business Overview
      • 6.4.10.2. Products/Services Offerings
      • 6.4.10.3. Financial Analysis
      • 6.4.10.4. SWOT Analysis
• 7. Global Fragment-based Drug Discovery Sale, by Type, End-users, Technology and Region (value) (2022-2027)
  • 7.1. Introduction
  • 7.2. Global Fragment-based Drug Discovery (Value)
    • 7.2.1. Global Fragment-based Drug Discovery by: Type (Value)
      • 7.2.1.1. Fragment Screening
      • 7.2.1.2. Fragment Optimization
    • 7.2.2. Global Fragment-based Drug Discovery by: End-users (Value)
      • 7.2.2.1. Academic and Research Institutions
      • 7.2.2.2. Biopharmaceutical Companies
      • 7.2.2.3. Contract Research Organizations
    • 7.2.3. Global Fragment-based Drug Discovery by: Technology (Value)
      • 7.2.3.1. NMR Spectroscopy
      • 7.2.3.2. Differential Scanning Fluorimetry (DSF) Assay
      • 7.2.3.3. Fluorescence Polarization
      • 7.2.3.4. Isothermal Titration Calorimetry
      • 7.2.3.5. X-Ray Crystallography
      • 7.2.3.6. Surface Plasmon Resonance (SPR)
      • 7.2.3.7. Others
    • 7.2.4. Global Fragment-based Drug Discovery Region
      • 7.2.4.1. South America
        • 7.2.4.1.1. Brazil
        • 7.2.4.1.2. Argentina
        • 7.2.4.1.3. Rest of South America
      • 7.2.4.2. Asia Pacific
        • 7.2.4.2.1. China
        • 7.2.4.2.2. Japan
        • 7.2.4.2.3. India
        • 7.2.4.2.4. South Korea
        • 7.2.4.2.5. Taiwan
        • 7.2.4.2.6. Australia
        • 7.2.4.2.7. Rest of Asia-Pacific
      • 7.2.4.3. Europe
        • 7.2.4.3.1. Germany
        • 7.2.4.3.2. France
        • 7.2.4.3.3. Italy
        • 7.2.4.3.4. United Kingdom
        • 7.2.4.3.5. Netherlands
        • 7.2.4.3.6. Rest of Europe
      • 7.2.4.4. MEA
        • 7.2.4.4.1. Middle East
        • 7.2.4.4.2. Africa
      • 7.2.4.5. North America
        • 7.2.4.5.1. United States
        • 7.2.4.5.2. Canada
        • 7.2.4.5.3. Mexico
• 8. Appendix
  • 8.1. Acronyms
• 9. Methodology and Data Source
  • 9.1. Methodology/Research Approach
    • 9.1.1. Research Programs/Design
    • 9.1.2. Market Size Estimation
    • 9.1.3. Market Breakdown and Data Triangulation
  • 9.2. Data Source
    • 9.2.1. Secondary Sources
    • 9.2.2. Primary Sources
  • 9.3. Disclaimer

• Table 1. Fragment-based Drug Discovery: by Type(USD Million)
• Table 2. Fragment-based Drug Discovery Fragment Screening , by Region USD Million (2016-2021)
• Table 3. Fragment-based Drug Discovery Fragment Optimization , by Region USD Million (2016-2021)
• Table 4. Fragment-based Drug Discovery: by End-users(USD Million)
• Table 5. Fragment-based Drug Discovery Academic and Research Institutions , by Region USD Million (2016-2021)
• Table 6. Fragment-based Drug Discovery Biopharmaceutical Companies , by Region USD Million (2016-2021)
• Table 7. Fragment-based Drug Discovery Contract Research Organizations , by Region USD Million (2016-2021)
• Table 8. Fragment-based Drug Discovery: by Technology(USD Million)
• Table 9. Fragment-based Drug Discovery NMR Spectroscopy , by Region USD Million (2016-2021)
• Table 10. Fragment-based Drug Discovery Differential Scanning Fluorimetry (DSF) Assay , by Region USD Million (2016-2021)
• Table 11. Fragment-based Drug Discovery Fluorescence Polarization , by Region USD Million (2016-2021)
• Table 12. Fragment-based Drug Discovery Isothermal Titration Calorimetry , by Region USD Million (2016-2021)
• Table 13. Fragment-based Drug Discovery X-Ray Crystallography , by Region USD Million (2016-2021)
• Table 14. Fragment-based Drug Discovery Surface Plasmon Resonance (SPR) , by Region USD Million (2016-2021)
• Table 15. Fragment-based Drug Discovery Others , by Region USD Million (2016-2021)
• Table 16. South America Fragment-based Drug Discovery, by Country USD Million (2016-2021)
• Table 17. South America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 18. South America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 19. South America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 20. Brazil Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 21. Brazil Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 22. Brazil Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 23. Argentina Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 24. Argentina Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 25. Argentina Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 26. Rest of South America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 27. Rest of South America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 28. Rest of South America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 29. Asia Pacific Fragment-based Drug Discovery, by Country USD Million (2016-2021)
• Table 30. Asia Pacific Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 31. Asia Pacific Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 32. Asia Pacific Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 33. China Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 34. China Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 35. China Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 36. Japan Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 37. Japan Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 38. Japan Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 39. India Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 40. India Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 41. India Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 42. South Korea Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 43. South Korea Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 44. South Korea Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 45. Taiwan Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 46. Taiwan Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 47. Taiwan Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 48. Australia Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 49. Australia Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 50. Australia Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 51. Rest of Asia-Pacific Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 52. Rest of Asia-Pacific Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 53. Rest of Asia-Pacific Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 54. Europe Fragment-based Drug Discovery, by Country USD Million (2016-2021)
• Table 55. Europe Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 56. Europe Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 57. Europe Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 58. Germany Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 59. Germany Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 60. Germany Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 61. France Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 62. France Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 63. France Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 64. Italy Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 65. Italy Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 66. Italy Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 67. United Kingdom Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 68. United Kingdom Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 69. United Kingdom Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 70. Netherlands Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 71. Netherlands Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 72. Netherlands Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 73. Rest of Europe Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 74. Rest of Europe Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 75. Rest of Europe Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 76. MEA Fragment-based Drug Discovery, by Country USD Million (2016-2021)
• Table 77. MEA Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 78. MEA Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 79. MEA Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 80. Middle East Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 81. Middle East Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 82. Middle East Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 83. Africa Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 84. Africa Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 85. Africa Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 86. North America Fragment-based Drug Discovery, by Country USD Million (2016-2021)
• Table 87. North America Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 88. North America Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 89. North America Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 90. United States Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 91. United States Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 92. United States Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 93. Canada Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 94. Canada Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 95. Canada Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 96. Mexico Fragment-based Drug Discovery, by Type USD Million (2016-2021)
• Table 97. Mexico Fragment-based Drug Discovery, by End-users USD Million (2016-2021)
• Table 98. Mexico Fragment-based Drug Discovery, by Technology USD Million (2016-2021)
• Table 99. Company Basic Information, Sales Area and Its Competitors
• Table 100. Company Basic Information, Sales Area and Its Competitors
• Table 101. Company Basic Information, Sales Area and Its Competitors
• Table 102. Company Basic Information, Sales Area and Its Competitors
• Table 103. Company Basic Information, Sales Area and Its Competitors
• Table 104. Company Basic Information, Sales Area and Its Competitors
• Table 105. Company Basic Information, Sales Area and Its Competitors
• Table 106. Company Basic Information, Sales Area and Its Competitors
• Table 107. Company Basic Information, Sales Area and Its Competitors
• Table 108. Company Basic Information, Sales Area and Its Competitors
• Table 109. Fragment-based Drug Discovery: by Type(USD Million)
• Table 110. Fragment-based Drug Discovery Fragment Screening , by Region USD Million (2022-2027)
• Table 111. Fragment-based Drug Discovery Fragment Optimization , by Region USD Million (2022-2027)
• Table 112. Fragment-based Drug Discovery: by End-users(USD Million)
• Table 113. Fragment-based Drug Discovery Academic and Research Institutions , by Region USD Million (2022-2027)
• Table 114. Fragment-based Drug Discovery Biopharmaceutical Companies , by Region USD Million (2022-2027)
• Table 115. Fragment-based Drug Discovery Contract Research Organizations , by Region USD Million (2022-2027)
• Table 116. Fragment-based Drug Discovery: by Technology(USD Million)
• Table 117. Fragment-based Drug Discovery NMR Spectroscopy , by Region USD Million (2022-2027)
• Table 118. Fragment-based Drug Discovery Differential Scanning Fluorimetry (DSF) Assay , by Region USD Million (2022-2027)
• Table 119. Fragment-based Drug Discovery Fluorescence Polarization , by Region USD Million (2022-2027)
• Table 120. Fragment-based Drug Discovery Isothermal Titration Calorimetry , by Region USD Million (2022-2027)
• Table 121. Fragment-based Drug Discovery X-Ray Crystallography , by Region USD Million (2022-2027)
• Table 122. Fragment-based Drug Discovery Surface Plasmon Resonance (SPR) , by Region USD Million (2022-2027)
• Table 123. Fragment-based Drug Discovery Others , by Region USD Million (2022-2027)
• Table 124. South America Fragment-based Drug Discovery, by Country USD Million (2022-2027)
• Table 125. South America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 126. South America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 127. South America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 128. Brazil Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 129. Brazil Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 130. Brazil Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 131. Argentina Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 132. Argentina Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 133. Argentina Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 134. Rest of South America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 135. Rest of South America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 136. Rest of South America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 137. Asia Pacific Fragment-based Drug Discovery, by Country USD Million (2022-2027)
• Table 138. Asia Pacific Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 139. Asia Pacific Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 140. Asia Pacific Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 141. China Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 142. China Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 143. China Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 144. Japan Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 145. Japan Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 146. Japan Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 147. India Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 148. India Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 149. India Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 150. South Korea Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 151. South Korea Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 152. South Korea Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 153. Taiwan Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 154. Taiwan Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 155. Taiwan Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 156. Australia Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 157. Australia Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 158. Australia Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 159. Rest of Asia-Pacific Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 160. Rest of Asia-Pacific Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 161. Rest of Asia-Pacific Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 162. Europe Fragment-based Drug Discovery, by Country USD Million (2022-2027)
• Table 163. Europe Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 164. Europe Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 165. Europe Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 166. Germany Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 167. Germany Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 168. Germany Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 169. France Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 170. France Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 171. France Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 172. Italy Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 173. Italy Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 174. Italy Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 175. United Kingdom Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 176. United Kingdom Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 177. United Kingdom Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 178. Netherlands Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 179. Netherlands Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 180. Netherlands Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 181. Rest of Europe Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 182. Rest of Europe Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 183. Rest of Europe Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 184. MEA Fragment-based Drug Discovery, by Country USD Million (2022-2027)
• Table 185. MEA Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 186. MEA Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 187. MEA Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 188. Middle East Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 189. Middle East Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 190. Middle East Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 191. Africa Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 192. Africa Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 193. Africa Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 194. North America Fragment-based Drug Discovery, by Country USD Million (2022-2027)
• Table 195. North America Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 196. North America Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 197. North America Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 198. United States Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 199. United States Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 200. United States Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 201. Canada Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 202. Canada Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 203. Canada Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 204. Mexico Fragment-based Drug Discovery, by Type USD Million (2022-2027)
• Table 205. Mexico Fragment-based Drug Discovery, by End-users USD Million (2022-2027)
• Table 206. Mexico Fragment-based Drug Discovery, by Technology USD Million (2022-2027)
• Table 207. Research Programs/Design for This Report
• Table 208. Key Data Information from Secondary Sources
• Table 209. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Fragment-based Drug Discovery: by Type USD Million (2016-2021)
• Figure 5. Global Fragment-based Drug Discovery: by End-users USD Million (2016-2021)
• Figure 6. Global Fragment-based Drug Discovery: by Technology USD Million (2016-2021)
• Figure 7. South America Fragment-based Drug Discovery Share (%), by Country
• Figure 8. Asia Pacific Fragment-based Drug Discovery Share (%), by Country
• Figure 9. Europe Fragment-based Drug Discovery Share (%), by Country
• Figure 10. MEA Fragment-based Drug Discovery Share (%), by Country
• Figure 11. North America Fragment-based Drug Discovery Share (%), by Country
• Figure 12. Global Fragment-based Drug Discovery share by Players 2021 (%)
• Figure 13. Global Fragment-based Drug Discovery share by Players (Top 3) 2021(%)
• Figure 14. Global Fragment-based Drug Discovery share by Players (Top 5) 2021(%)
• Figure 15. BCG Matrix for key Companies
• Figure 16. Astex Pharmaceuticals (United Kingdom) Revenue, Net Income and Gross profit
• Figure 17. Astex Pharmaceuticals (United Kingdom) Revenue: by Geography 2021
• Figure 18. Alveus Pharmaceuticals (India) Revenue, Net Income and Gross profit
• Figure 19. Alveus Pharmaceuticals (India) Revenue: by Geography 2021
• Figure 20. Beactica (Sweden) Revenue, Net Income and Gross profit
• Figure 21. Beactica (Sweden) Revenue: by Geography 2021
• Figure 22. Charles River Laboratories (United States) Revenue, Net Income and Gross profit
• Figure 23. Charles River Laboratories (United States) Revenue: by Geography 2021
• Figure 24. Crown Bioscience (United States) Revenue, Net Income and Gross profit
• Figure 25. Crown Bioscience (United States) Revenue: by Geography 2021
• Figure 26. Emerald BioStructures (United States) Revenue, Net Income and Gross profit
• Figure 27. Emerald BioStructures (United States) Revenue: by Geography 2021
• Figure 28. Evotec (Germany) Revenue, Net Income and Gross profit
• Figure 29. Evotec (Germany) Revenue: by Geography 2021
• Figure 30. Kinetic Discovery (United Kingdom) Revenue, Net Income and Gross profit
• Figure 31. Kinetic Discovery (United Kingdom) Revenue: by Geography 2021
• Figure 32. Proteros Fragments (Germany) Revenue, Net Income and Gross profit
• Figure 33. Proteros Fragments (Germany) Revenue: by Geography 2021
• Figure 34. Structure Based Design (United States) Revenue, Net Income and Gross profit
• Figure 35. Structure Based Design (United States) Revenue: by Geography 2021
• Figure 36. Global Fragment-based Drug Discovery: by Type USD Million (2022-2027)
• Figure 37. Global Fragment-based Drug Discovery: by End-users USD Million (2022-2027)
• Figure 38. Global Fragment-based Drug Discovery: by Technology USD Million (2022-2027)
• Figure 39. South America Fragment-based Drug Discovery Share (%), by Country
• Figure 40. Asia Pacific Fragment-based Drug Discovery Share (%), by Country
• Figure 41. Europe Fragment-based Drug Discovery Share (%), by Country
• Figure 42. MEA Fragment-based Drug Discovery Share (%), by Country
• Figure 43. North America Fragment-based Drug Discovery Share (%), by Country

• Astex Pharmaceuticals (United Kingdom)
• Alveus Pharmaceuticals (India)
• Beactica (Sweden)
• Charles River Laboratories (United States)
• Crown Bioscience (United States)
• Emerald BioStructures (United States)
• Evotec (Germany)
• Kinetic Discovery (United Kingdom)
• Proteros Fragments (Germany)
• Structure Based Design (United States)